Drugs by condition
Drugs approved for hepatitis c
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
13
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
7
New molecular entities and new biologics
In development
3
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for hepatitis c.
- Alvaiz (Eltrombopag Choline) · Teva Pharms INC Nov 29, 2023
- Epclusa (Sofosbuvir, Velpatasvir) · Gilead Sciences INC Priority reviewOrphanJun 10, 2021
- Mavyret (Glecaprevir, Pibrentasvir) · Abbvie Breakthrough therapyPriority reviewOrphanJun 10, 2021
- Harvoni (Ledipasvir, Sofosbuvir) · Gilead Sciences INC Priority reviewOrphanAug 28, 2019
- Sovaldi (Sofosbuvir) · Gilead Sciences INC Priority reviewOrphanAug 28, 2019
All approved drugs for hepatitis c, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 15 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Hepatitis C Virus NS5A Inhibitor (6)
- Mavyret Glecaprevir, Pibrentasvir · Abbvie · 2017
- Epclusa Sofosbuvir, Velpatasvir · Gilead Sciences INC · 2016
- Harvoni Ledipasvir, Sofosbuvir · Gilead Sciences INC · 2014
- Epclusa Sofosbuvir, Velpatasvir · Gilead Sciences INC · 2021
- Mavyret Glecaprevir, Pibrentasvir · Abbvie · 2021
- Harvoni Ledipasvir, Sofosbuvir · Gilead Sciences INC · 2019
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor (3)
Interferon alpha (1)
- Pegasys Peginterferon Alfa-2a · Pharmaand Gmbh · 2002
Class not listed in FDA's data (3)
- Promacta Eltrombopag Olamine · Novartis · 2008
- Alvaiz Eltrombopag Choline · Teva Pharms INC · 2023
- Promacta Kit Eltrombopag Olamine · Novartis · 2015
Drugs in development for hepatitis c
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- Bemnifosbuvir-RuzasvirBEM, RZRPhase 32 trials
Atea Pharmaceuticals, Inc. · HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection
- BemnifosbuvirAT-527Phase 21 trial
Atea Pharmaceuticals, Inc. · Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C
- RuzasvirAT-038Phase 21 trial
Atea Pharmaceuticals, Inc. · Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C
1 discontinued brand-name drugs whose label still names it
- Zepatier Elbasvir, Grazoprevir
More on hepatitis c: recruiting trials · published research
Related in infectious disease and vaccines: HIV · Hepatitis B · COVID-19 · Influenza · RSV · Urinary tract infection · Pneumonia · Skin infections · C. difficile infection · Fungal infections
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.